Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies.

[1]  N. Letvin,et al.  Effect of Preexisting Immunity to Adenovirus Human Serotype 5 Antigens on the Immune Responses of Nonhuman Primates to Vaccine Regimens Based on Human- or Chimpanzee-Derived Adenovirus Vectors , 2007, Journal of Virology.

[2]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.

[3]  A. Stryhn,et al.  Alteration of epitope recognition pattern in Ag85B and ESAT‐6 has a profound influence on vaccine‐induced protection against Mycobacterium tuberculosis , 2006, European journal of immunology.

[4]  A. Parker,et al.  Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. , 2006, Blood.

[5]  K. Mansfield,et al.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.

[6]  K. Ulbrich,et al.  Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells , 2006, Gene Therapy.

[7]  D. Collen,et al.  Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. , 2005, Human gene therapy.

[8]  S. Kochanek,et al.  Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  A. Gaggar,et al.  Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity , 2005, Journal of Virology.

[10]  B. Walker,et al.  Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1 , 2005, The Journal of Immunology.

[11]  P. Krebs,et al.  Rapid Functional Exhaustion and Deletion of CTL following Immunization with Recombinant Adenovirus1 , 2005, The Journal of Immunology.

[12]  A. Beaudet,et al.  PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile , 2005, Gene Therapy.

[13]  Hildegund C.J. Ertl,et al.  Adenoviruses as vaccine vectors , 2004, Molecular Therapy.

[14]  D. Moon,et al.  Imaging of human sodium-iodide symporter gene expression mediated by recombinant adenovirus in skeletal muscle of living rats , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  S. Kostense,et al.  Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 , 2004, The Journal of Immunology.

[16]  S. Kostense,et al.  Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.

[17]  R. K. Evans,et al.  Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene , 2003, Journal of Virology.

[18]  D. Collen,et al.  Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells. , 2003, Blood.

[19]  James M. Wilson,et al.  PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. , 2002, Human gene therapy.

[20]  S. Ylä-Herttuala,et al.  Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ , 2002, The journal of gene medicine.

[21]  S. Kochanek,et al.  A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. , 2002, Human gene therapy.

[22]  James M. Wilson,et al.  “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung , 2001, Journal of Virology.

[23]  S. Kochanek,et al.  Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. , 2000, Human gene therapy.

[24]  J. Wilson,et al.  Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. , 2000, Human gene therapy.

[25]  F. Chisari,et al.  Ongoing Murine T1 or T2 Immune Responses to the Hepatitis B Surface Antigen Are Excluded from the Liver that Expresses Transgene-Encoded Hepatitis B Surface Antigen1 , 2000, The Journal of Immunology.

[26]  D. Metz,et al.  The liver as a site of T‐cell apoptosis: graveyard, or killing field? , 2000, Immunological reviews.

[27]  R. Offringa,et al.  Adenoviruses Activate Human Dendritic Cells without Polarization toward a T-Helper Type 1-Inducing Subset , 1999, Journal of Virology.

[28]  H. Romanczuk,et al.  Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. , 1999, Human gene therapy.

[29]  A. Juedes,et al.  Selective retention of activated CD8+ T cells by the normal liver. , 1999, Journal of immunology.

[30]  Alan E. Smith,et al.  PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. , 1999, Human gene therapy.

[31]  T. Libermann,et al.  Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. , 1999, Human gene therapy.

[32]  James M. Wilson,et al.  Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. , 1998, Human gene therapy.

[33]  M. Barry,et al.  Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  S. Gurunathan,et al.  DNA vaccines: immunology, application, and optimization*. , 2000, Annual review of immunology.